Welcome to Bayside Health | Alfred. More information about Bayside Health can be found at baysidehealth.org.au

Contact About Find a doctor Careers The Alfred Foundation For staff

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Clear filter

636 clinical trials found

Clinical trials

CLB-4000-1-001

A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNa-2a in Subjects with Chronic Hepatitis B (ACTRN12625000204448)

A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNa-2a in Subjects with Chronic Hepatitis B

Currently recruiting

CLEOPATTRA

CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy [ATTR-CM] (NCT07207811)

This study aims to determine whether a new medication, NNC6019-0001, can lower the risk of heart-related complications in people diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), a disease that affects the heart. Participants will be randomly assigned to receive either NNC6019-0001 or a placebo, which contains no active drug. Throughout the study, all participants will continue their standard heart treatments as advised by their healthcare provider.

Coming soon

CLN-619-001

A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Immunoregulatory Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors (NCT05117476)

Currently recruiting

CLOU064C12306

A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by open-label treatment with remibrutinib (NCT06846281)

Currently recruiting

CLOU064J12301

A randomized, double-blind, double-dummy, placebocontrolled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis suppurativa (NCT06799000)

Currently recruiting

CLOU064M12301

A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines (NCT05976243)

No longer recruiting

CMBG453E12101

A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome (NCT04810611)

Currently recruiting

CML14 ASCENDENCE

ASCENDANCE - ASCiminib Evaluation in Newly diagnosed CML with Dasatinib to Augment response in Complex genomic Etiology (ACTRN12623001338651)

At the start of the trial, Patients will have genetic testing and all patients will then receive treatment with Asciminib monotherapy at 80mg daily for the first four weeks, while the genetic results are analysed. Patients are then split into high or standard risks groups based on their genetic results. Patients determined to be at standard risk will continue to receive 80mg daily Asciminib monotherapy while high risk patients will receive combination therapy of: 80mg of Asciminib daily and 50mg of Dasatinib daily. Overall treatment duration is upto 2 years.

Currently recruiting

COALA Study

COALA Trial: Changing Outcomes After Low Anterior resection in colorectal cancer by anal sphincter prehabilitation prior to reversal of ileostomy – a parallel explanatory (COALA-1) and pragmatic trial (COALA-2) (Trial registration pending)

Currently recruiting

COALITION

A multicentre, parallel arm, open-label trial of frontline R-CHOP/Pola-RCHP and glofitamab in younger, higher risk patients with diffuse large B cell lymphoma (DLBCL) (COALITION) (NCT04914741)

No longer recruiting

COBRRA

COmparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism (COBRRA) (NCT03266783)

Currently recruiting

Codebreak-202 20190341

A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202) (NCT05920356)

Currently recruiting

COGENT

D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT): A Multi-Site, Randomised, Placebo-Controlled Trial (ACTRN12622001359729)

Currently recruiting

Cognition in Progressive Supranuclear Palsy

Assessing cognitive trajectories in Progressive Supranuclear Palsy using remote computerized reaction time tasks (Trial Not Registered)

This study aims to assess the potential role for remote computerised cognitive battery measurements in detecting short-term cognitive decline in PSP, and to explore its role as a novel biomarker for disease progression in descriptive and therapeutic clinical trials.

Currently recruiting

COLLIGO

mavaCamten Observational evidence Global cOnsortium in HCM [COLLIGO-HCM] (NCT06372457)

The aim of this study is to investigate treatments and real-world effectiveness for hypertrophic cardiomyopathy (HCM), including examining the path to diagnosis, disease progression, and the new treatment for obstructive HCM (o-HCM), mavacamten. This protocol localisation for COLLIGO-HCM is for The Alfred Hospital participating site in Australia. It will address only a subset of the objectives from the master protocol which were deemed applicable after conducting feasibility.

Currently recruiting

COMB157GAU01

Secondary use of data study characterizing Kesimpta (ofatumumab) onboarding and utilization in RMS patients using MSGo, with a non-interventional primary use of data sub-study comparing Patient Reported Outcomes relative to Clinical Outcomes (EAFToS) (NCT05090033)

No longer recruiting

CONNEX X

An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEXX) (NCT05211947)

Currently recruiting

CONNEX-1

A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-1) (NCT04846868)

Currently recruiting

CORE

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (NCT05079919)